# MEVPRO-1: HCP commentary report

> 284 verified statements (106 from speakers with a confirmed clinical role) from 41 commentary sources · 9 findings · updated Oct 19, 2026

## Report

- Trial: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
- NCT ID: NCT06551324
- Registry: https://clinicaltrials.gov/study/NCT06551324
- Sponsor: Pfizer
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs: docetaxel, enzalutamide
- Version: v1.0.0, edition 1
- Accepted: 2026-10-19
- Last checked: 2026-10-19
- Release hash: 6a4f7362ff34fc7a2804b9273826ff3774d8c7358ca61dd1380fa22b4f629412

## Counts

- HCP commentary sources screened: 46
- Sources cited by verified statements: 41
- Verified statements: 284
- From speakers with a confirmed clinical role: 106
- Findings: 9
- People found in screened sources: 21
- People identity-verified: 11
- Voices cited: 20

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

MEVPRO-1 asks which treatment should come next after abiraterone in metastatic castration-resistant prostate cancer, comparing mevrometostat plus enzalutamide with docetaxel or enzalutamide. Clinicians discuss how to assess that choice through earlier efficacy and safety evidence, PSA and imaging outcomes, resistance biology, lineage plasticity and biomarker work-up. Other topics include PARP-based and radiopharmaceutical alternatives, treatment sequencing, and access to testing, multidisciplinary care and clinical trials.

## Open Medical Affairs question

What evidence would distinguish a clinically useful alternative to docetaxel from an improvement over enzalutamide switching alone?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The consequential question is whether the combination offers a better next treatment—not merely a better ARPI switch
- F2. The earlier efficacy signal generates enthusiasm, but speakers still require pivotal confirmation
- F3. Favorable tolerability assessments coexist with gastrointestinal burden and other visible adverse effects
- F4. One discussion questions whether PSA response has the same meaning across PRC2 inhibition and radioligand therapy
- F5. Resistance and lineage-plasticity biology explain interest, but prevention and biomarker selection remain hypotheses
- F6. Prior ARPI progression and molecular work-up constrain extrapolation from other combination strategies
- F7. Radiopharmaceutical alternatives are patient- and timing-dependent, with bone protection and marrow burden central
- F8. Testing, timely sequencing and care infrastructure are implementation concerns—not secondary details
- F9. Patient and caregiver accounts add access context but are not evidence of HCP endorsement or comparative efficacy

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 11 | 8 | 4 | 5 | recorded | 3 |
| F2 | 11 | 7 | 5 | 4 | recorded | 3 |
| F3 | 13 | 8 | 6 | 3 | recorded | 4 |
| F4 | 1 | 1 | 1 | 1 | none recorded | 3 |
| F5 | 15 | 12 | 5 | 6 | recorded | 3 |
| F6 | 13 | 10 | 3 | 3 | recorded | 4 |
| F7 | 14 | 9 | 4 | 4 | recorded | 4 |
| F8 | 14 | 13 | 4 | 3 | recorded | 4 |
| F9 | 14 | 9 | 1 | 0 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 5 | 1 | 1 | 2 | 2 | 12 | 1 | 1 post or article, 3 podcasts and video | yes |
| F2 | 5 | 1 | 0 | 2 | 3 | 13 | 2 | 1 post or article, 4 podcasts and video | yes |
| F3 | 5 | 2 | 0 | 0 | 6 | 14 | 3 | 1 post or article, 5 podcasts and video | yes |
| F4 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 post or article | yes |
| F5 | 8 | 3 | 2 | 0 | 2 | 24 | 9 | 2 posts and articles, 3 podcasts and video | yes |
| F6 | 5 | 1 | 0 | 0 | 7 | 35 | 1 | 3 podcasts and video | yes |
| F7 | 5 | 1 | 2 | 4 | 2 | 15 | 2 | 4 podcasts and video | yes |
| F8 | 10 | 1 | 0 | 1 | 2 | 18 | 0 | 4 podcasts and video | yes |
| F9 | 2 | 4 | 6 | 1 | 1 | 15 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3): F2 (4 shared claims), F4 (1 shared claims)
- Secondary endpoints: F2 (3 shared claims), F3 (3 shared claims), F4 (1 shared claims)
- Population and setting: F6 (6 shared claims)
- The comparison: F1 (7 shared claims)
- Safety and tolerability: F2 (1 shared claims), F3 (10 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. The consequential question is whether the combination offers a better next treatment—not merely a better ARPI switch

A YouTube panel addressed what MEVPRO-1 should clarify about treatment after abiraterone, including the choice between docetaxel and mevrometostat plus enzalutamide.

The discussion concerns an individual patient and does not present MEVPRO-1 treatment outcomes.

Source: YouTube video, 2025-06-25.

### F4. One discussion questions whether PSA response has the same meaning across PRC2 inhibition and radioligand therapy

An X-thread discussion raised how PSA response relates to radiographic progression-free survival when considering mevrometostat plus enzalutamide alongside radioligand therapy.

The author's clinical role is not stated in the sources reviewed for this edition.

The combination population included patients previously treated with taxanes, whereas the radioligand population was taxane-naive.

The cited predictor analysis was post-hoc and concerned radioligand treatment. The MEVPRO-1 question was forward-looking, not a report of its results.

Source: X thread, 2026-04-01.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 284 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 41 | Counts free |
| Speaker attribution for cited voices | 20 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) | discussed | 5 | 4 |
| Secondary endpoints | discussed | 6 | 5 |
| Population and setting | discussed | 7 | 3 |
| The comparison | discussed | 10 | 4 |
| Safety and tolerability | discussed | 10 | 6 |
| Design and conduct | discussed | 7 | 5 |
| EZH2 rationale, lineage plasticity and aggressive-variant disease | discussed | 23 | 6 |
| Biomarker work-up and applicability of PARP-based alternatives after prior ARPI | discussed | 18 | 4 |
| Radiopharmaceutical alternatives, skeletal protection and sequencing | discussed | 15 | 4 |
| Timely treatment, testing access and multidisciplinary support | discussed | 16 | 4 |
| Patient and caregiver experience of treatment switching and research access | discussed | 14 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 35 | 31 |
| YouTube | 9 | 8 |
| Podcasts | 2 | 2 |

- Screened window: 2024-12-04 to 2026-10-16
- Cited window: 2024-12-04 to 2026-10-01
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
- Registry: NCT06551324 (https://clinicaltrials.gov/study/NCT06551324)
- Study IDs: C2321014 · 2024-511650-50-00 (CTIS (EU))
- Sponsor: Pfizer
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 600 (estimated)
- Start: 2024-10-21 (actual)
- Primary completion: 2026-12-28 (estimated)
- Primary endpoint: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (Randomization up to approximately 2 years.)
- Intervention: PF-06821497 (drug)
- Intervention: Docetaxel (drug)
- Intervention: Enzalutamide (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 8 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 147 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion, and trial-unnamed discussion may be underrepresented.
- Some relevant discussion of PARP-combination alternatives and biomarker-based selection was not fully evaluated; the range of views may therefore be incomplete.
- Repeated posts and multiple recordings of the same session cannot be counted as independent clinician opinions or separate clinical experiences.
- Some speakers remain unidentified. Titles, participant lists and professional profiles do not establish who voiced those passages.
- Clinical roles for Emir C. Roach, Rashid K. Sayyid and Rishabh Jain are not established in the sources reviewed. Patient, caregiver, publisher and financial commentary should not be treated as independent HCP judgment.
- Earlier efficacy and safety observations are speaker reports from supporting studies, not MEVPRO-1 phase III outcomes. Differences in reported study phase and prior chemotherapy exposure remain unresolved.
- Contemporaneous trial-design descriptions are inconsistent about the control comparison. The complete protocol was unavailable, so these remarks cannot resolve operational details.
- An exact mevrometostat regulatory label was unavailable. Speaker descriptions of approvals, eligibility and reimbursement reflect their stated time and geography rather than independently verified current guidance.
- Several numerical estimates concern selected databases, small groups, post-hoc analyses or individual experience; they do not support population-wide rates, causal comparisons or a treatment hierarchy.
- Support-group treatment and insurance accounts are personal reports. They cannot establish comparative efficacy, molecular eligibility, payment guarantees or recommended self-directed treatment.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-19: current edition

Last checked for new commentary 2026-10-19. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (284 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/mevpro-1-nct06551324
- Agents: POST https://www.erudio.com/api/orders with {"report": "mevpro-1-nct06551324", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=mevpro-1-06551324

## Cite

Erudio Health. MEVPRO-1 (NCT06551324): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 19, 2026. https://www.erudio.com/reports/mevpro-1-nct06551324

## Machine access

- JSON: https://www.erudio.com/reports/mevpro-1-nct06551324.json
- Markdown: https://www.erudio.com/reports/mevpro-1-nct06551324.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "mevpro-1-06551324"}`